Market Overview

BioCryst Files Peramivir NDA for Influenza

BioCryst
Pharmaceuticals, (NASDAQ: BCRX) today announced that it has submitted a New
Drug Application (NDA) filing for intravenous (i.v.) peramivir
to the U.S. Food & Drug Administration (FDA). BioCryst is seeking an
indication as the first i.v. neuraminidase inhibitor approved in the
U.S. for the treatment of acute uncomplicated influenza in adults.
Peramivir is approved in Japan and Korea for the treatment of influenza.

See full press release

Posted-In: News Guidance Contracts FDA Management Global

 

Most Popular

Related Articles (BCRX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters